{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50.9","upperLimit":"81.4","value":"67.5"},{"groupId":"OG001","lowerLimit":"60.6","upperLimit":"88.0","value":"76.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"Percentage of participants with complete response as assessed by Response Evaluation Criteria in Solid Tumors (Phase II) according to treatment arm. Participants are planned to be treated for a total of 6 cycles (21 day cycle length). Participants with CR after Cycle 4 will receive two additional cycles of chemotherapy and complete 6 cycles of chemotherapy. Participants who achieve a partial response (PR) only after Cycle 4 may continue on protocol therapy or they may be removed from the study at the AMC discretion of the physician (local Principal Investigator). Participants with stable disease after 4 cycles (i.e., who did not achieve at least a PR) or progressive disease at any time will be removed from study.\n\nIn phase II, there are two arms: Vorinostat RPTD+rituximab-DA-EPOCH arm (VR-DA-EPOCH) and Rituximab-DA-EPOCH arm (DA-R-EPOCH).","dispersionType":"95% Confidence Interval","groups":[{"description":"Arm A (VR-DA-EPOCH) at the recommended phase II dose of Vorinostat (300 mg once a day for days 1-5 of a cycle)","id":"OG000","title":"Phase II: VR-DA-EPOCH"},{"description":"Arm B (DA-R-EPOCH), which is the same treatment as Arm A, but without Vorinostat","id":"OG001","title":"Phase II: DA-R-EPOCH"}],"paramType":"NUMBER","populationDescription":"Reviewed responses from participants who completed at least one cycle of treatment. In phase II, there are two arms: Vorinostat RPTD+rituximab-DA-EPOCH arm (VR-DA-EPOCH) and Rituximab-DA-EPOCH arm (DA-R-EPOCH).\n\nIn phase I, patients in DA-R-EPOCH were not included in the analysis.","reportingStatus":"POSTED","timeFrame":"Up to 6 months","title":"Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}